BioSpace News Archive

AlzeCure Pharma AlzeCure Pharma AB, a pharmaceutical company that develops a broad portfolio of drug candidates for diseases affecting the central nervous system, with projects in both Alzheimer’s disease and pain, announced that the company’s presentation at the pain conference EFIC 2023 is now available in its entirety on the company’s website.

Alvotech, a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced that the U.S. Food and Drug Administration has accepted Alvotech’s resubmitted Biologics License Application for AVT02, a high-concentration, interchangeable biosimilar candidate to Humira®.

Chroma Medicine, Inc., a genomic medicine company pioneering single-dose epigenetic editing therapeutics, presented positive preclinical data demonstrating the potential of its epigenetic editors to produce efficacious, specific, and durable silencing of the hepatitis B virus during the HBV International Meeting 2023, held September 19-23 in Kobe, Japan.